Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments.

Kroenke, Mark A; Weeraratne, Dohan K; Deng, Hongjie; Sloey, Bethlyn; Subramanian, Raju; Wu, Benjamin; Serenko, Michael; Hock, M Benjamin

Kroenke, Mark A; Weeraratne, Dohan K; Deng, Hongjie; Sloey, Bethlyn; Subramanian, Raju; Wu, Benjamin; Serenko, Michael; Hock, M Benjamin.

Afiliação

Kroenke MA; Amgen Inc., Medical Sciences, Thousand Oaks, CA, United States.
Weeraratne DK; Amgen Inc., Pharmacokinetics and Drug Metabolism, Thousand Oaks, CA, United States.
Deng H; Amgen Inc., Global Biostatistical Sciences, Thousand Oaks, CA, United States.
Sloey B; Amgen Inc., Medical Sciences, Thousand Oaks, CA, United States.
Subramanian R; Amgen Inc., Pharmacokinetics and Drug Metabolism, Thousand Oaks, CA, United States.
Wu B; Amgen Inc., Medical Sciences, Thousand Oaks, CA, United States.
Serenko M; Amgen Inc., Global Safety, Cambridge, MA, United States.
Hock MB; Amgen Inc., Medical Sciences, Thousand Oaks, CA, United States. Electronic address: mhock@amgen.com.

J Immunol Methods ; 445: 37-44, 2017 06.

Article em En | MEDLINE | ID: mdl-28274835

Assuntos

Imunoensaio; Peptídeos/imunologia; Ressonância de Plasmônio de Superfície; Animais; Anticorpos/imunologia; Humanos; Coelhos

Palavras-chave

ADA impact assessment; Anti-drug antibody; Calcimimetic; Etelcalcetide; Immunogenicity; Surface plasmon resonance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Imunoensaio / Ressonância de Plasmônio de Superfície Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: J Immunol Methods Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google